The following are examples where KZE principals are authors or acknowledged as writers or editors.

Publications

S Gordon, V Ameen, B Bagby, et al. Validation of the Irritable Bowel Syndrome Global Improvement Scale: An Integrated Symptom Endpoint for Assessing Treatment Efficacy. Dig Dis Sci 48(7):1317-23, 2003.

T Lembo, RA Wright, B Bagby, et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 96(9):2662-70, 2001.

M Camilleri, WY Chey, EA Mayer, et al. A randomize, controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Int Med. 161: 1733-40, 2001.

NJ Talley, S Veldhuyzen van Zanten, G Dukes, et al, Dose-ranging, randomized, placebo-controlled, clinical trial of alosetron in subjects with functional dyspepsia Ailment Pharm Therapeutics: 15(4):525-37, 2001.

SG Wolfe, WY Chey, MK Washington, et al. Tolerability and safety of alosetron during long-term administration in female and male IBS patients, Am J Gastroenterology: 96(3):803-11, 2001.

JF Ricci, P Jhingran, T McLaughlin, PhD, E Carter. Costs of Care for Irritable Bowel Syndrome in Managed Care. J Clin Outcomes Management, 7: 23-28, 2000.

M Camilleri, AR Northcutt, S Kong, et al. The efficacy and safety of alosetron in female patients with irritable bowel syndrome: a randomized, placebo controlled study. Lancet, 225:1035-40, 2000.

SS Murthy, T Shen, A DeRienzo, WC Lee, PC Ferriola, et al. Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene. 19(3):410-6, 2000.

A Peng, S Milleri, DS Stein. Direct measurement of the anti-influenza compound zanamivir in the respiratory tract following inhaled administration. Antimic Agents Chemother, 44: 1974-76, 2000.

A Peng, EK Hussey, KHP Moore. A population pharmacokinetic analysis of zanamivir in subjects with experimental and naturally occurring influenza J Clin Pharm, 40:242-49, 1999.

CA DeAbate, D Myers, D Henry, et al. Comparative efficacy and tolerability of once-daily grepafloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis. Clin Drug Investigation, 17(1):21-31,1999.

DC Henry, GE Ruoff, M Noonan, et al. Comparative efficacy and tolerability of short-course (5-days) cefuroxime axetil with amoxicillin/clavulanate (10-days) in the treatment of secondary bacterial infections of acute bronchitis Clin Drug Invest, 1999.

R Jones, G Holtmann G, L Rodrigo, et al. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharm Ther, 13: 1419-1427, 1999.

DA Baker, JG Blythe, JM Miller. Once-daily valacyclovir for suppression of recurrent genital herpes. Obstet Gynecol, 93 103-6, 1999.

CE Langan, F Zuck, A Vogel, et al. Comparative efficacy and safety of short-course (five-day) grepafloxacin versus ten-day clarithromycin for the treatment of acute bacterial exacerbations of chronic bronchitis. J Antimic Chemother, 1999.

PC Ferriola and W Stewart. Fibronectin organization and expression in mesothelial and mesothelioma cells. Am. J. Physiology 271:804-12, 1996.

PC Ferriola. Autocrine growth factors and the extracellular matrix: key players in the pathogenesis of lung and pleural cell cancers. In: Eighteenth Annual Interdisciplinary Cancer Research Workshop, C Parkanyi and P Politzer P, eds. Cancer Biochem. Biophys. 15: 199-206, 1996.

SH Randell, JY Liu, PC Ferriola, et al. Regulation of mucin production in SPOC1 cells: an airway epithelial mucous goblet cell line. Am. J. Resp. Cell Mol. Biol. 14:146-154, 1996.

MM Doherty, JY Liu, et al., and Ferriola, P.C.: Phenotype and differentiation potential of a novel airway epithelial cell line. Am. J. Resp. Cell Mol. Biol. 12:385-95, 1995.

MA Bonham, S Brown, AL Boyd, PH Brown, DA Bruckenstein DA, et al.: An assessment of the antisense properties of RNase H-competent and steric-blocking oligomers. Nucleic Acid Research, 7:1197-1203, 1995.

PC Ferriola and P Nettesheim. Regulation of normal and transformed tracheobronchial epithelial cell proliferation by autocrine growth factors. Critical Reviews in Oncogenesis 5:107-120, 1994.

CA Carter, MM Doherty, R Rusnak, P Nettesheim and PF Ferriola. Alterations in the localization of F-actin, fibronectin, and thrombospondin occur prior to neoplastic transformation in rat tracheal epithelial cells. Exp. Cell Res. 212:141-150, 1994.

T Iwanaga and PC Ferriola. Cellular uptake of phosphorothioate oligodeoxynucleotides is negatively affected by cell density in a transformed airway epithelial cell line. Biochem. Biophys. Res. Comm. 191:1152-57, 1993.

JC Hanvey, NJ Peffer, JE Bisi, SA Thomson, R Cadilla, JA Josey, CF Hassman, A Bonham, KG Au, SG Carter, DA Bruckenstein, AL Boyd, SA Noble and LE Babiss. Antisense and Antigene Properties of Peptide Nucleic Acids. Science, 258:1481-1485, 1992.

PC Ferriola and P Nettesheim. Alterations in growth factor pathways during multistage carcinogenesis of rat tracheal epithelial cells. J. Radiation Research 2:277-287, 1992.

PC Ferriola, AT Robertson, DW Rusnak, et al. Epidermal growth factor dependence and TGFa autocrine growth regulation in primary rat tracheal epithelial cells. J. Cell. Physiology 152:302-309, 1992.

PC Ferriola, HS Earp, R DiAugustine and P Nettesheim. The role of TGFa and its receptor in proliferation of transformed rat tracheal epithelial cells. J. Cell. Physiology 147:166-175, 1991.

PC Ferriola, AT Robertson, R Steigerwalt and P Nettesheim. Abnormalities in growth regulation of transformed rat tracheal epithelial cells. Pathobiology 58:28-36, 1990.

PC Ferriola, C Walker, C., Robertson, et al. Alterations in growth factor requirements and transforming growth factor gene expression in transformed rat tracheal epithelial cells. Molec Carcinogenesis 2(6):336-344, 1989.

PC Ferriola, V Cody, and EM Middleton. Protein kinase C inhibition by plant flavonoids: kinetic mechanisms and structure-activity relationships. Biochemical Pharmacol. 38:1617-1624, 1989.

EM Middleton, PC Ferriola, G Drzewiecki, and RD Sophia. The effect of azelastine and other anti-asthmatic and anti-allergy drugs on calmodulin and protein kinase C. Agents and Actions, 28:9-15, 1989.

EM Middleton and PC Ferriola. Effect of flavonoids on PKC: relationship to inhibition of human basophil histamine release. In: Plant Flavonoids in Biology and Medicine II: Biochemical, Cellular and Medicinal Properties, EM Middleton, V Cody and J Harborne, eds., New York: Alan R. Liss, Inc., 1988.

EM Middleton, PC Ferriola and G Drzewiecki. Effect of flavonoids on tumor promoter induced basophil histamine release and protein kinase C. Trans. Amer. Clin. Climatol. Assoc. 100:47-56, 1988.

EM Middleton and PC Ferriola. Effect of flavonoids on protein kinase C: relationship to inhibition of human basophil histamine release. Prog Clin Biol Res 280: 251-66, 1988.

PJ Horvath, PC Ferriola, MM Weiser, andME Duffey, Localization of chloride secretion in the rabbit colon by inhibition with A-9-C. Am. J. Physiol. 250:G185-190, 1986.

PC Ferriola, MA Acara, and ME Duffey. Thiazide diuretics inhibit chloride absorption across rabbit colon. J. Pharmacol. Exp. Ther. 238:912-915, 1986.

VM Vogt, DA Bruckenstein and A.P.Bell. Avian Sarcoma virus “gag” precursor polypeptide is not processed in mammalian cells. J. Virology, 44:725-730, 1982.

Strategic Documents

Publication Plans

Five-year publication plan for a chemotherapeutic agent in development for colon cancer and pancreatic cancer.

Three-year publication plan for an immunotherapeutic vaccine in development for breast cancer.

Planned Publication Steering Committee objectives for key opinion leaders authoring Phase III manuscript for an immunotherapeutic vaccine.

Five-year publication plan for a novel 5-HT3 receptor antagonist for IBS.

Secondary and tertiary journal publication plan for a novel 5-HT4 agonist for IBS.

Health outcomes publication plan for a novel 5-HT4 agonist for IBS.

One-year publication plan for a marketed drug for genital and oral herpes simplex.

Two-year publication plan for a marketed antibiotic for acute sinusitis and bronchitis.

Three-year publication plan for a fluoroquinolone antibiotic in development for respiratory infections.

Five-year publication plan for an influenza drug in late-stage clinical development.

Competitive Analyses and Therapeutic Area Assessments

Product positioning analysis for a chemotherapeutic agent in development for treatment of solid tumors.

Analysis comparing press release activity, trial activity, and key messages/themes for 6 small molecule targeted cancer therapeutics in development for solid tumors and hematologic malignancies.

Environmental Landscape analysis (key themes and issues impacting on development of a publication and communication plan) for a novel opiate agonist for IBS.

Competitive analysis (press release activity, publications and meeting abstracts, and other publicly available information such as company web sites to identify product positioning, key milestones and communication strategies for IBS products in development and marketed.

White Papers and Case Studies

Critical assessment of a high throughput chemical synthesis and screening technology used to identify new chemotherapeutics with improved toxicity profiles.

IBS training module for sales representatives.

Itineraries and summaries for proceedings of international GI meetings.

Newsletter on “Optimizing Value in Asthma Management”.

Ferriola, PC, Ambroso, JL, Patrone, LM, Stedman, DB and Welsch, F.: Localizing and quantifying toxicological responses with confocal laser scanning microscopy. CIIT Activities 16(6): 1-8, 1996.

A review of asbestos and cancer for the chemical industry: Everitt, JI, Bermudez, E., Mangum, JB and Ferriola, PC: Malignant mesothelioma: A legacy of asbestos that affects the safety evaluation of synthetic vitreous fibers. CIIT Activities 16(9): 1-6, 1996.